Doguizi Sibel, Sekeroglu Mehmet A, Inanc Merve, Anayol Mustafa A, Yilmazbas Pelin
Department of Ophthalmology, Ulucanlar Eye Training and Research Hospital, Ankara - Turkey.
Eur J Ophthalmol. 2018 Jan;28(1):63-67. doi: 10.5301/ejo.5001001.
To evaluate the pain associated with intravitreal aflibercept injections.
The study included 119 patients who received intravitreal aflibercept injection at a single institution. Pain was evaluated by visual analog scale (VAS) immediately after the injection of 2 mg/0.05 mL aflibercept into the vitreous cavity using a 27-G needle. Additional variables including age, sex, indication for the injection, injection site by quadrant (superotemporal or inferotemporal), position during injection (sitting or supine), number of previous intravitreal injections in the study eye, presence of diabetes mellitus or hypertension, and lens status (phakic or pseudophakic) were recorded and assessed with self-reported pain scores.
Pain scores on the VAS ranged from 9 to 70, with a median of 18. Indications for injection included diabetic macular edema (21.0%), macular edema secondary to central retinal vein occlusion (12.6%), and neovascular age-related macular degeneration (66.38%). Pain did not significantly correlate with any of the recorded variables.
This is the first series evaluating the pain associated with intravitreal aflibercept injections. We demonstrated that pain associated with intravitreal aflibercept injection is generally mild with low pain scores.
评估玻璃体内注射阿柏西普相关的疼痛。
该研究纳入了119例在单一机构接受玻璃体内阿柏西普注射的患者。使用27G针头将2mg/0.05mL阿柏西普注入玻璃体腔后，立即通过视觉模拟量表（VAS）评估疼痛程度。记录其他变量，包括年龄、性别、注射指征、象限注射部位（颞上或颞下）、注射时的体位（坐姿或仰卧位）、研究眼既往玻璃体内注射次数、是否患有糖尿病或高血压以及晶状体状态（有晶状体或人工晶状体），并与自我报告的疼痛评分进行评估。
VAS疼痛评分范围为9至70，中位数为18。注射指征包括糖尿病性黄斑水肿（21.0%）、视网膜中央静脉阻塞继发的黄斑水肿（12.6%）和新生血管性年龄相关性黄斑变性（66.38%）。疼痛与任何记录的变量均无显著相关性。
这是首个评估玻璃体内注射阿柏西普相关疼痛的系列研究。我们证明，玻璃体内注射阿柏西普相关的疼痛通常较轻，疼痛评分较低。
